" class="no-js "lang="en-US"> XWPharma - Medtech Alert
Thursday, March 30, 2023

Breaking News

Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Implantica Launches RefluxStop™ in Italy Granular Therapeutics to Accelerate Development of Next-Generation Pipeline for Treating Mast Cell Driven Diseases Xeris Biopharma Appoints Ricki Fairley to Board of Directors AskBio to Present Phase 1b Results Investigating AB-1005 as Treatment for Parkinson’s Disease New Imaging Method for Evaluating Transport of Oxygen to Blood Cells Hansa Biopharma Announces Positive Reimbursement in Spain for Idefirix as Desensitization Treatment for Patients in Kidney Transplantation Coeptis Therapeutics Secures Exclusive Rights to Negotiate the Acquisition of Transformational Cell Therapy Platform SamaCare Partners with AmerisourceBergen to Offer Prior Authorization Platform to Specialty Practices
XWPharma | Pharmtech Focus

XWPharma

About XWPharma

XWPharma

We are a biotech with a neuroscience pipeline of internally discovered novel small molecule drug candidates focused on sleep, neuropysch and other underserved neurological conditions.

Related Story

Clinical Trials

 XWPharma Initiates First-in-Human Studies of XW10508

XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain

October 19 2021

Avance Clinical, the largest premium Australian CRO for international biotechs, is pleased to share the […]